CSL is a global biotech leader, estimated to be worth US$45 billion. Our dedicated management and employees are driven to fulfill our promise to patients to deliver life-saving and life-improving therapies that help many thousands of people live full livesClick here to view investor information on csl.com
Search Results105 results found
The fair value is calculated using a Black-Scholes methodology and, for Options and Performance Rights subject to a market condition, a Monte Carlo simulation model which takes into consideration factors such as the performance hurdles and probability of those hurdles being achieved, share price volatility, life of the award, dividend yield, risk free rate and share price at grant.
FY17 total dividend A$1.75 / float share price adjusted for share split A$0.77 7 |
Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at market open.
A$ A$B 250 Share Price 140 Market Capitalisation
19 The face value is calculated using a share price of A$227.31 being the share price on the date of grant - 1 September 2018.
A$ A$B 350 Share Price 140 Market Capitalisation
A$ A$B 180 Share Price 140 Market Capitalisation
Share Based Payment Plans Commitments A face value equity allocation methodology, being a volume weighted average share price based on the market price of a CSL share at the time of grant, is used Commitments in relation to capital expenditure contracted but not provided for in to determine the number of units granted to a participant under each of the shared the financial statements are payable as follows:
Despite the increase in CSL's share price over the past 4-5 years, private investors have not been deterred from buying CSL shares, with the number of shareholders increasing from less than 100,000 to more than 150,000.